Keith Meister Buys 29,495 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Keith Meister purchased 29,495 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were bought at an average price of $70.89 per share, with a total value of $2,090,900.55. Following the purchase, the director owned 3,088,124 shares in the company, valued at $218,917,110.36. This represents a 0.96% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

GeneDx Stock Up 7.5%

Shares of WGS stock opened at $88.11 on Friday. The stock’s 50 day simple moving average is $100.80 and its 200 day simple moving average is $122.16. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of -117.48 and a beta of 2.03.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.03. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. The business had revenue of $120.99 million during the quarter, compared to the consensus estimate of $120.80 million. As a group, research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Large affiliated/institutional buy: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, a strong signal of institutional confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
• Positive Sentiment: Director buying: Director Keith A. Meister made two recent purchases (140,026 shares on Mar 5 at ~$81.19 and 29,495 shares on Mar 3 at ~$70.89), increasing his stake to over 3.2M shares — a large insider accumulation that typically signals confidence and can drive demand. SEC ownership filing — Keith A. Meister purchases
• Positive Sentiment: Recent earnings beat: GeneDx topped consensus on its most recent quarterly EPS and delivered revenue roughly in line with estimates, supporting a bullish narrative around recurring revenue and margin progress (analyst consensus remains a Moderate Buy with elevated price targets).
• Neutral Sentiment: Short-interest reading shows 0 reported short interest as of Mar 5, which appears to be a data anomaly and offers little actionable signal on immediate directional pressure.
• Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 (~$2.0M) and cut her direct stake materially. Significant insider sales can worry some investors about insiders taking liquidity. SEC Form 4 — CEO sale
• Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 (~$486k), trimming his position by roughly 25%; this adds to mixed insider signals even though the size is smaller than the institutional buys. SEC Form 4 — CFO sale

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on WGS shares. Canaccord Genuity Group raised their price objective on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Wells Fargo & Company raised GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price objective on the stock in a report on Monday, February 9th. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research report on Monday, February 23rd. Piper Sandler restated an “overweight” rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Finally, Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $150.71.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of WGS. Kestra Advisory Services LLC bought a new stake in GeneDx during the 4th quarter worth approximately $27,000. Jones Financial Companies Lllp raised its position in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the last quarter. Ramirez Asset Management Inc. acquired a new position in GeneDx in the fourth quarter worth $33,000. Greenline Wealth Management LLC bought a new stake in shares of GeneDx during the fourth quarter worth $33,000. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in GeneDx in the 4th quarter valued at about $35,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.